Roche announced that the SATURN (SequentiAl Tarceva in UnResectable NSCLC) study met its primary endpoint of progression free survival. The study showed that Tarceva (erlotinib), when given in first line maintenance - immediately following initial treatment with platinum-based chemotherapy - significantly extended the time patients with advanced non-small cell lung cancer (NSCLC) lived without their cancer getting worse.
The details can be read here.
No comments:
Post a Comment